Stenocare As Stock Fundamentals
| STENO Stock | DKK 2.04 0.14 7.37% |
Stenocare AS fundamentals help investors to digest information that contributes to Stenocare's financial success or failures. It also enables traders to predict the movement of Stenocare Stock. The fundamental analysis module provides a way to measure Stenocare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stenocare stock.
Stenocare |
Stenocare AS Company Return On Equity Analysis
Stenocare's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Stenocare Return On Equity | -0.49 |
Most of Stenocare's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stenocare AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Stenocare AS has a Return On Equity of -0.4924. This is 97.95% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all Denmark stocks is 58.84% higher than that of the company.
Stenocare AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Stenocare's current stock value. Our valuation model uses many indicators to compare Stenocare value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Stenocare competition to find correlations between indicators driving Stenocare's intrinsic value. More Info.Stenocare AS is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Stenocare by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Stenocare's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Stenocare Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stenocare's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Stenocare could also be used in its relative valuation, which is a method of valuing Stenocare by comparing valuation metrics of similar companies.Stenocare is currently under evaluation in return on equity category among its peers.
Stenocare Fundamentals
| Return On Equity | -0.49 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (11.44) % | |||
| Current Valuation | 119.1 M | |||
| Shares Outstanding | 11.42 M | |||
| Shares Owned By Insiders | 38.59 % | |||
| Price To Book | 4.21 X | |||
| Price To Sales | 67.34 X | |||
| Gross Profit | (6.01 M) | |||
| EBITDA | (12.96 M) | |||
| Net Income | (12.73 M) | |||
| Cash And Equivalents | 20.42 M | |||
| Cash Per Share | 1.79 X | |||
| Current Ratio | 6.49 X | |||
| Book Value Per Share | 2.40 X | |||
| Cash Flow From Operations | (13.34 M) | |||
| Earnings Per Share | (1.17) X | |||
| Beta | 0.11 | |||
| Market Capitalization | 106.1 M | |||
| Total Asset | 43.94 M | |||
| Net Asset | 43.94 M |
About Stenocare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stenocare AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stenocare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stenocare AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Stenocare AS cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products in the Danish and European markets. The company was founded in 2017 and is headquartered in Allerd, Denmark. STENOCARE is traded on Copenhagen Stock Exchange in Denmark.
Pair Trading with Stenocare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Stenocare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stenocare will appreciate offsetting losses from the drop in the long position's value.Moving together with Stenocare Stock
The ability to find closely correlated positions to Stenocare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Stenocare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Stenocare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Stenocare AS to buy it.
The correlation of Stenocare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Stenocare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Stenocare AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Stenocare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Stenocare Stock
Stenocare financial ratios help investors to determine whether Stenocare Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stenocare with respect to the benefits of owning Stenocare security.